{"id":"W1976250589","doi":"10.1016/s1470-2045(13)70026-3","title":"Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":166,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Amgen","keywords":"Exemestane; Fulvestrant; Postmenopausal women; Medicine; Oncology; Breast cancer; Hormone receptor; Internal medicine; Aromatase inhibitor; Cancer; Gynecology; Aromatase; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006701979,0.000585935,0.002294787,0.0001325364,0.0002689876,0.00006325055,0.0003445294,0.0002596639,0.0006940754],"category_scores_gemma":[0.0000507334,0.0002705147,0.0001309639,0.000352771,0.0004597266,0.000301098,0.00003215199,0.0005628249,0.00005918075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004983331,"about_ca_system_score_gemma":0.001155735,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002745045,"about_ca_topic_score_gemma":0.0001088687,"domain_scores_codex":[0.9968248,0.0002239416,0.0007117525,0.0006031679,0.000422092,0.001214233],"domain_scores_gemma":[0.9972328,0.0007007585,0.0005110123,0.0005707893,0.0005672463,0.0004174238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9639683,0.001424702,0.00005265075,0.00005526023,0.001451709,0.00009267,0.001613254,0.000008681293,0.01678216,0.0001409223,0.003012154,0.01139748],"study_design_scores_gemma":[0.928259,0.06042133,0.0006058699,0.00007801797,0.0008505852,0.0006081636,0.001458198,0.00005302445,0.001110044,0.00004715888,0.006078456,0.0004301279],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699981,0.0005630102,0.0002909287,0.009309033,0.0002991251,0.01698895,0.0002434584,0.0001421803,0.002165226],"genre_scores_gemma":[0.9779209,0.0006028351,0.001011282,0.002590415,0.001731127,0.0147421,0.0001118996,0.0001224669,0.001166979],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05899663,"threshold_uncertainty_score":0.9999747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03208678168695916,"score_gpt":0.3278753074354844,"score_spread":0.2957885257485253,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}